Abstract
Purpose
Intradetrusor onabotulinum toxin A (BTX-A) has been demonstrated to be an effective treatment option for overactive bladder (OAB). However, concerns about frailty and frequent injections may deter its use in the elderly. This study aims to assess the safety, efficacy, and treatment duration of BTX-A in managing OAB in elderly women.
Methods
We retrospectively reviewed female patients aged 70 and above who were diagnosed with OAB with predominant urge urinary incontinence and underwent intravesical BTX-A treatment. We collected demographic and clinical data, with repeat BTX-A injections re-administered upon patient-reported symptom recurrence.
Results
Twenty-one female patients, median age 77 (range 71–92), were included. The median time between the first and second injection was 185 (84–448) days, 186 (105–959) days between the second and third injection, and increased to 206.5 (84–256) days between the third and fourth injection. However, the median interval trended downward after the fourth injection (Fig. 1). Patients with four or more injections had a shorter median interval between injections, 154 days, compared to those with fewer injections, 210 days. Two patients (6.9%) experienced urinary retention after the initial treatment, with 1 (2.2%) among a total of 46 subsequent treatments (Table 3). There were ten (13.3%) episodes of UTIs within 2 weeks of treatment. Patients reported improvement in symptoms following 93.3% of the injections.
Conclusion
This real-world study demonstrates that BTX-A effectively controls OAB symptoms in elderly women, with just two injections annually. BTX-A appears safe and efficacious for treating OAB in elderly females.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data availability
The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.
References
Stewart WF et al (2003) Prevalence and burden of overactive bladder in the United States. World J Urol 20:327–336
Reynolds WS, Fowke J, Dmochowski R (2016) The burden of overactive bladder on US public health. Curr Bladder Dysfunct Rep 11:8
Cui Y et al (2013) Botulinum toxin-A injections for idiopathic overactive bladder: a systematic review and meta-analysis. Urol Int 91:429–438
Cruz F et al (2011) Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Eur Urol 60:742–750
Irwin DE et al (2006) Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 50:1306–1315
Schurch B et al (2005) Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol 174:196–200
Beijer HJM, De Blaey CJ (2002) Hospitalisations caused by adverse drug reactions (ADR): a meta-analysis of observational studies. Pharm World Sci 24:46–54
Kouladjian O’Donnell L, Gnjidic D, Nahas R, Bell JS, Hilmer SN (2017) Anticholinergic burden: considerations for older adults. J Pharm Pract Res 47:67–77
Rovner E et al (2011) Urodynamic results and clinical outcomes with intradetrusor injections of onabotulinumtoxina in a randomized, placebo-controlled dose-finding study in idiopathic overactive bladder. Neurourol Urodyn 30:556–562
Dmochowski R et al (2010) Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial. J Urol 184:2416–2422
Nitti VW et al (2013) OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol 189:2186–2193
Sahai A, Dowson C, Khan MS, Dasgupta P (2009) Improvement in quality of life after botulinum toxin-A injections for idiopathic detrusor overactivity: results from a randomized double-blind placebo-controlled trial. BJU Int 103:1509–1515
Orasanu B, Mahajan ST (2013) The use of botulinum toxin for the treatment of overactive bladder syndrome. Indian J Urol 29:2
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors have no relevant financial or non-financial interests to disclose.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Basin, M.F., Chadha, P., Useva, A. et al. Investigation of intradetrusor onabotulinum toxin A efficacy and safety in older adults with urge urinary incontinence. Int Urol Nephrol 56, 1559–1563 (2024). https://doi.org/10.1007/s11255-023-03891-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11255-023-03891-9